January 5, 2021

Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19

Xabier García-Albéniz MD PhD [1,2], Julia del Amo MD PhD [3], Rosa Polo MD PhD [3], José Miguel Morales-Asencio PhD[4], Miguel A Hernán MD DrPH[2,5]

[1] RTI Health Solutions. Barcelona, Spain

[2] Department of Epidemiology. Harvard T.H. Chan School of Public Health. Boston, MA, USA

[3] National Plan Against AIDS, Ministry of Health. Madrid, Spain

[4] Department of Nursing and Podiatry, Universidad de Málaga, Málaga, Spain.

[5] Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA

Correspondence: Xabier Garcia-Albeniz. RTI Health Solutions. Av. Diagonal, 605, 9-1. 08028. Barcelona, Spain, xgarcia@rti.org

Word count: 2372

Abstract

Background: Recruitment into randomized trials of hydroxychloroquine (HCQ) for prevention of COVID-19 has been adversely affected by a widespread conviction that HCQ is not effective for prevention. In the absence of an updated systematic review, we conducted a meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID-19.

Methods: A search of PubMed and medRxiv with expert consultation found five completed randomized trials: two pre-exposure prophylaxis trials and three post-exposure prophylaxis trials. We obtained or calculated the risk ratio of COVID-19 diagnosis for assignment to HCQ versus no HCQ (either placebo or usual care) for each trial, and then pooled the risk ratio estimates.

Results: The estimated risk ratios were 0.74 (95% CI 0.50-1.10), 0.95 (0.25, 3.64) for the pre-exposure prophylaxis trials, and 0.83 (95% CI: 0.58-1.18), 0.68 (95% CI: 0.34-1.34) and 1.10 (95% CI 0.76-1.61) for the post-exposure prophylaxis trials. The pooled risk ratio estimate was 0.86 (95% CI: 0.70-1.06) when using either a fixed effect or a standard random effects approach, and 0.86 (95% CI: 0.65-1.15) when using a conservative modification of the Hartung-Knapp random effects approach. All five trials found a similar rate of serious adverse effects in the HCQ and no HCQ groups.

Discussion: A benefit of HCQ cannot be ruled out based on the 5 completed trials, but the "not statistically significant" findings from two early trials were widely interpreted as definite evidence of lack of effectiveness of HCQ for prophylaxis of COVID-19. This interpretation disrupted the timely completion of the remaining trials and thus the generation of precise estimates for pandemic management before the development of vaccines.

Background

Hydroxychloroquine (HCQ) is not an effective treatment for established coronavirus disease 2019 (COVID-19) (1, 2), but it is unclear whether HCQ can prevent symptomatic COVID-19. Early in the SARS-CoV-2 pandemic, about 30 randomized trials were designed to study the prophylactic effect of HCQ (3). After the findings from two of these trials were reported in the Summer of 2020 (4, 5), HCQ was generally viewed by the medical community as ineffective for COVID-19 prophylaxis. The emergence of that consensus was surprising because both trials found a lower risk of COVID-19 in the HCQ group, were too small to rule out either benefit or harm of HCQ, and had significant methodological limitations.

A timely completion of the remaining trials would have generated precise estimates of the potential effectiveness of HCQ to prevent COVID-19 among those at high risk of infection or complications. However, the widespread conviction about HCQ's lack of effectiveness dramatically slowed down the recruitment into ongoing trials of HCQ prophylaxis (some of them carried out by the authors of this report) (6). As a result, key decisions were made based on insufficient evidence during the pre-vaccine period of the pandemic.

In the absence of an updated systematic review, we conducted a meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID-19 either before known exposure to an infected individual (pre-exposure prophylaxis) or after known exposure to an infected individual (post-exposure prophylaxis).

Methods

Studies were eligible for inclusion if they were randomized clinical trials comparing hydroxychloroquine as prophylaxis (pre-exposure or post-exposure) for COVID-19 with a

non-active control, included individuals who were PCR-negative at the time of treatment assignment, had been completed, and had the full text published in a peer-reviewed journal or as a pre-print. Given the relatively small number of trials conducted so far, we identified candidate studies through expert consultation and confirmed the findings with a search of PubMed and medRxiv as of January 2, 2021, using the search strategy in the Appendix. Two authors (XGA and MAH) independently reviewed the full text of the identified studies and extracted the data. Disagreements were resolved by consulting other co-authors (JdA, RP). Incomplete or unpublished data were requested from the investigators of each trial. The risk of bias of the included studies was assessed independently by 2 authors (XGA, MAH) using the "Rob 2" tool by the Cochrane Bias Methods Group (7).

For each of the identified trials, we obtained or calculated the risk ratio of COVID-19 for assignment to HCQ versus no HCQ (either placebo or usual care) among PCR-negative individuals at baseline. Our primary analysis is based on the definition of COVID-19 reported in the primary analysis of each study. Also, we tried to harmonize the definition of COVID-19 across studies by conducting separate meta-analyses among those studies that reported "laboratory-confirmed COVID-19 diagnosis" and among those that reported "laboratory-confirmed or clinically-probable COVID-19 diagnosis".

We calculated the pooled risk ratio estimate and its 95% confidence or compatibility interval (CI) using a fixed (or common) effect approach and two types of random effects approaches (8, 9). The standard random effects method has been shown to yield an anticonservative (that is, too narrow) 95% CI (8). The alternative Hartung-Knapp random effects method (9) has been shown to generally outperform the standard random effects method (10), but it results in an even more anticonservative 95% CI (narrower than the 95% CI from the standard method) when, as in our meta-analysis, the estimated between-study heterogeneity is small (tau-

squared near zero) (11, 12). We therefore used the Hartung-Knapp method with an ad hoc modification (13) designed to ensure that its 95% CI remains wider than that of the standard method, even though the resulting 95% CI is expected to be conservative (too wide) when, as in our meta-analysis, the number of studies is small (14). All analyses were conducted in Stata (version 16.1; Stata Corporation, College Station, Texas, USA).

Results

Five completed randomized trials were identified (4, 5, 15-17). Two trials studied hydroxychloroquine as pre-exposure prophylaxis (15, 16) and three as post-exposure prophylaxis (4, 5, 17). Our risk of bias assessment identified the handling of incomplete ascertainment of the outcome and the exclusion of patients after randomization as possible sources of moderate bias (see Supplementary Material).

The two pre-exposure prophylaxis trials were double-blinded, placebo-controlled trials that included healthcare workers with ongoing exposure to patients with COVID-19. In the first one (16), the risk of COVID-19 was 5.9% (58 total cases, 11 confirmed by PCR) among 989 participants assigned to HCQ (two 400 mg doses on day 1, followed by 400 mg either once or twice weekly for 12 weeks) and 7.9% (39 total cases, 6 confirmed by PCR) among 494 participants assigned to placebo. The estimated risk difference was -2.0% (95% CI -4.8, 0.8) and the risk ratio was 0.74 (95% CI 0.50, 1.10). In the second trial (15), the risk of COVID-19 was 6.3% (4 cases confirmed by PCR) among 64 participants assigned to HCQ (600 mg daily for 8 weeks) and 6.6% (4 cases confirmed by PCR) among 61 participants assigned to placebo. The estimated risk difference was -0.3% (95% CI -8.9, 8.3) and the risk ratio 0.95 (95% CI 0.25, 3.64).

The three post-exposure prophylaxis trials included asymptomatic contacts of confirmed COVID-19 cases. The first one was a double-blind, placebo-controlled trial in which the risk of COVID-19 diagnosis (largely based on compatible symptoms) was 11.8% in 414 contacts assigned to HCQ (800 mg. on day 1, 600 mg. daily for four days) and 14.3% in 407 contacts assigned to placebo. The risk difference was -2.4% (95% CI: -7.0, 2.2) and the risk ratio can be calculated as 0.83 (95% CI: 0.58, 1.18). The second one (5) was an open-label, cluster-randomized trial in which the COVID-19 risk (based on confirmed PCR) was 3.0% in 958 contacts assigned to HCQ (800 mg. on day 1, 400 mg. daily for six days) and 4.3% in 1042 contacts assigned to usual care. The risk ratio (adjusted for age, gender, region, and time of exposure) was 0.68 (95% CI: 0.34, 1.34); the corresponding risk difference cannot be directly calculated from the data provided. The third study (17) was a double-blind, placebo-controlled cluster-randomized trial in which the COVID-19 risk (also based on confirmed PCR) was 15.0% in 353 contacts assigned to HCQ (400 mg/d orally for 3 days, then 200 mg/d orally for 11 days) and 13.4% in 336 contacts assigned to placebo (ascorbic acid 500 mg/d orally for 3 days, then 250 mg/d orally for 11 days). The adjusted risk ratio (provided by the authors) was 1.10 (95% CI 0.76, 1.61).

The time from exposure to initiation of prophylaxis was relatively long in the three post-exposure prophylaxis trials: in one trial, about a third of participants were enrolled 4 days after exposure (none was enrolled later) (4); in the other, about 10% of participants were enrolled 7 or more days after exposure (5); in the third study, 8% of participants received a first dose 5 days or later after exposure (17). For comparison, post-exposure prophylaxis for HIV is recommended in the first 6-72 hours after the exposure (18, 19).

The Figure shows the risk ratio estimates from each of the trials and the pooled estimates. The pooled risk ratio of COVID-19 for assignment to hydroxychloroquine vs. no

hydroxychloroquine was 0.86 (95% CI: 0.70-1.06) when using either a fixed effect or a standard random effects approach, and 0.86 (95% CI: 0.65-1.15) when using the ad hoc modification of the Hartung-Knapp approach. All five trials found a similarly low rate of serious adverse effects in the HCQ and no HCQ groups (4, 5, 15-17). As expected, the proportion of mild gastrointestinal side effects was greater in the HCQ group.

In an analysis of the outcome "laboratory-confirmed symptomatic COVID-19", the pooled risk ratio estimate was 0.91 (95% CI: 0.58-1.44) or 0.91 (95% CI: 0.44-1.92); in an analysis restricted to the three trials that reported "laboratory-confirmed or clinically-probable COVID-19" (4, 5, 16), the pooled risk ratio estimate was 0.89 (95% CI: 0.73-1.08) or 0.89 (95% CI: 0.58-1.37) (Supplementary Figures 1 and 2). The pooled risk ratio was 0.76 (95% CI 0.52-1.10) for the two pre-exposure prophylaxis studies (15, 16), and 0.91 (95% CI 0.71-1.16) for the three post-exposure prophylaxis studies (4, 5, 17) using a fixed effect approach.

Discussion

When considered together, the available randomized trials yield a point estimate of an approximately 10% lower risk of COVID-19 for assignment to HCQ compared with no HCQ among PCR-negative individuals at randomization. Any effect between a 30% reduction in risk and a 10% increase in risk is highly compatible with the data from these trials.

As studies appeared between June and September, the point estimate hovered around a 20% reduction with increasingly narrower compatibility intervals (Supplementary Figure 3). Yet throughout this entire period the opinion of many medical researchers was that HCQ was ineffective for prevention and that additional trials were unnecessary. The point estimate moved to around 10% reduction after the publication in December of a cluster-randomized

study (17). In this study, the proportion of individuals with negative PCR at baseline differed between randomized groups and no outcomes were recorded among individuals with unavailable PCR at baseline. The practical implications of these baseline imbalances are unclear but may have guided the investigators' decision to adjust for baseline variables, which was not contemplated in the study protocol (20).

Like in many meta-analyses, there was some degree of between-study heterogeneity with respect to the definition of the COVID-19 outcome, the period over which the outcome was ascertained, and the specifications of the interventions being studied. Despite these sources of design heterogeneity (which we summarize below), the point estimates from the studies included in the meta-analysis were similar and the statistical heterogeneity, as measured by the I^2, was close to zero.

When we attempted to harmonize the definition of COVID-19, the point estimates were closer to the null value than those of our primary analysis, with a similar or greater level of uncertainty. However, the available information was insufficient to adequately harmonize the outcomes, and thus our attempt at harmonization may have introduced some degree of selection bias or misclassification bias. Estimates for laboratory-confirmed COVID-19 are difficult to interpret because the limited access to testing for participants in two of the studies (4, 16), implies that their estimates are based on a non-random subset of the cases that should have been laboratory confirmed. Also, some test results were self-reported. Estimates for "laboratory-confirmed or clinically-diagnosed COVID-19" are difficult to interpret because this definition includes only symptomatic individuals in two of the studies (4, 16), but also asymptomatic individuals with a positive PCR in another one (5). Ideally, all studies would have used the same primary outcome as the trial by Mitjà et al. (5): symptomatic COVID-19 with laboratory confirmation.

The occurrence of COVID-19 was ascertained over different periods across the studies: two weeks in the studies of Boulware et al. (4), Mitja et al. (5) and Barnabas et al. (17), 8 weeks in the study by Abella et al. (15) and 12 weeks in the study by Rajasingham et al. (16). However, given the long half-life of HCQ (21), it is unlikely that variations in the order of weeks would be sufficient to substantially alter the trial estimates.

In addition, we made the a priori decision of pooling studies of pre-exposure and post-exposure prophylaxis as the mechanism of action of HCQ is thought to be similar for both preventive approaches (21). When we stratified the meta-analysis by pre- or post-exposure prophylaxis trials, the effect estimates were similar but even more imprecise. However, a discussion about the appropriateness of pooling these two types of studies is warranted. A long time from exposure to treatment initiation in post-exposure trials weakens the case for pooling studies of pre-exposure and post-exposure prophylaxis as the latter can resemble studies of early treatment. As the number of completed randomized trials increases and stratified analyses can provide meaningful estimates, it will be important that future meta-analyses present separate estimates for pre-exposure and post-exposure prophylaxis.

Since our pooled estimates are very imprecise, we would need additional studies to draw more precise inferences about the prophylactic effect, if any, of HCQ. Unfortunately, recruitment for those studies is being impeded by incorrect interpretations of the available randomized trial evidence. The findings from the first reported trials were widely (and incorrectly) portrayed as definite evidence of the lack of effectiveness of HCQ, simply because they were not “statistically significant” when taken individually. Thus, the common confusion between the concepts “no effect” and “no statistical significance” led many to

conclude that HCQ had no prophylactic effect (which may be a true but premature conclusion) when we can only conclude that the effect estimate is still too imprecise (22, 23).

Our pooled estimates are based on the design and analytic choices made by the investigators of each trial, sometimes in a context of limited access to testing for SARS-CoV-2. We encourage the investigators from these and future prophylaxis trials to coordinate analyses of individual-level data with standardized outcome definitions; corrections for differences in length of follow-up, treatment dose, and time since exposure; adjustment for losses to follow-up and other deviations from protocol (24); and adoption of a more causally-interpretable meta-analytic approach (25). We also encourage the authors of living systematic reviews to update their findings frequently when, as in this case, public opinion interferes with the generation of the very evidence that will feed their systematic review.

In summary, throughout most of the pre-vaccine period of the pandemic, the available evidence was compatible with HCQ being viable as prophylaxis for individuals at high risk of infection or complications. Yet an incorrect interpretation of early inconclusive studies interfered with the timely completion of the trials needed to make a final determination. The recent approval of effective SARS-CoV-2 vaccines makes this discussion less relevant for the current pandemic. It is important, however, to improve the process by which the medical community develops and interprets data before the next public health emergency arrives. To avoid he proliferation of small studies with different methodologies, national regulators and international health organizations can play a key role in the coordination and harmonization of the randomized trials that they approve or endorse.

Funding: None.

Acknowledgments: We thank Prof. Sander Greenland and Daniel Westreich for technical advice, Dr. Matthew Cefalu for constructive feedback on study outcomes, and Prof. Richard Riley, Dr. Tim Morrison, and Mr. David Fisher for constructive feedback on estimation methods for random effects meta-analysis. We thank Dr. Ruanne Barnabas and Torin Schaafsma for providing the risk ratio from their study for inclusion in this meta-analysis.

None of the authors have any conflict of interest

References

1. Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, García CH, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv. 2020:2020.10.15.20209817.
2. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England journal of medicine. 2020;383(21):2030-40.
3. Bienvenu AL, Marty AM, Jones MK, Picot S. Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. One health (Amsterdam, Netherlands). 2020;10:100141.
4. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine. 2020;383(6):517-25.
5. Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. New England Journal of Medicine. 2020.
6. Goldman JD. Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic. Clinical Infectious Diseases. 2020.
7. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986;7(3):177-88.
9. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Statistics in medicine. 2001;20(24):3875-89.
10. IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Medical Research Methodology. 2014;14(1):25.
11. Wiksten A, Rücker G, Schwarzer G. Hartung-Knapp method is not always conservative compared with fixed-effect meta-analysis. Statistics in medicine. 2016;35(15):2503-15.
12. Jackson D, Law M, Rücker G, Schwarzer G. The Hartung-Knapp modification for random-effects meta-analysis: A useful refinement but are there any residual concerns? Statistics in medicine. 2017;36(25):3923-34.
13. Röver C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. BMC Medical Research Methodology. 2015;15(1):99.
14. Partlett C, Riley RD. Random effects meta-analysis: Coverage performance of 95% confidence and prediction intervals following REML estimation. Statistics in medicine. 2017;36(2):301-17.
15. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA internal medicine. 2020.
16. Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.
17. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. Ann Intern Med. 2020.
18. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis.

19. [Consensus Document on post-exposure prophylaxis against HIV, HBV and HCV in adults and children]. Enfermedades infecciosas y microbiologia clinica. 2016;34(2):121.e1-15.
20. Barnabas RV, Brown E, Bershteyn A, Miller RS, Wener M, Celum C, et al. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):475.
21. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;71(15):732-9.
22. Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567(7748):305-7.
23. Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. European journal of epidemiology. 2016;31(4):337-50.
24. Hernán MA, Robins JM. Per-Protocol Analyses of Pragmatic Trials. The New England journal of medicine. 2017;377(14):1391-8.
25. Dahabreh IJ, Petito LC, Robertson SE, Hernán MA, Steingrimsson JA. Toward Causally Interpretable Meta-analysis: Transporting Inferences from Multiple Randomized Trials to a New Target Population. Epidemiology (Cambridge, Mass). 2020;31(3):334-44.

Figure. Risk ratio estimates of COVID-19 for hydroxychloroquine vs. no hydroxychloroquine in randomized trials of pre- and post-exposure prophylaxis, pooled and by study. These estimates are based on the definition of COVID-19 reported in the primary analysis of each study.



Supplementary Material

Supplementary Figure 1. Risk ratio estimates of "laboratory-confirmed, symptomatic COVID-19" for hydroxychloroquine vs. no hydroxychloroquine in randomized trials of pre- and post-exposure prophylaxis, pooled and by study.

Note: Estimates for the studies by Boulware et al. and by Rajasingham et al. are based on a nonrandom subset of the cases that should have been laboratory-confirmed because participants in these studies had limited access to testing. The adjusted risk ratio from Barnabas et al. was not available but the hazard ratio was 1.24 (95% CI 0.81-1.90).



Supplementary Figure 2. Risk ratio estimates of "laboratory-confirmed or clinically-probable COVID-19" for hydroxychloroquine vs. no hydroxychloroquine in randomized trials of pre- and post-exposure prophylaxis, pooled and by study.

Note: The estimate for the study by Mitjà et al. is based on a set of cases that includes asymptomatic individuals.



Supplementary Figure 3. Risk ratio estimates of COVID-19 (as reported in the primary analysis of each study) for hydroxychloroquine vs. no hydroxychloroquine in randomized trials of pre- and post-exposure prophylaxis, pooled as evidence gathered over time. Confidence intervals are computed using the standard random effects method.



PubMed search strategy:

("hydroxychloroquine"[MeSH Terms] OR "hydroxychloroquine"[All Fields]) AND (("Pre-Exposure Prophylaxis"[Mesh]) OR "Post-Exposure Prophylaxis"[Mesh] OR prophylaxis[Title]) AND (("severe acute respiratory syndrome coronavirus 2"[Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2"[All Fields] OR "SARS-CoV-2"[All Fields]) AND ("COVID-19"[All Fields] OR "COVID-2019"[All Fields] OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2"[All Fields] OR "2019-nCoV"[All Fields] OR "SARS-CoV-2"[All Fields] OR "2019nCoV"[All Fields] OR ("Wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields]) AND (2019/12/01:2019/12/31[Date - Publication] OR 2020/01/01:2020/12/31[Date - Publication])))) AND ("Clinical Trial"[Publication Type] OR "Clinical Trials as Topic"[MeSH Terms] OR "trial*"[Title]) NOT (“Review”[Publication Type] OR “Systematic review”[Publication Type]) NOT (“Animals”[Mesh] NOT “Humans”[Mesh])

Risf of Bias

Cochrane risk of bias 2.0 tool assessment of randomized trials

	Rajasingham et al, 2020	Abella et al, 2020	Boulware et al, 2020	Mitja et al, 2020	Barnabas et al, 2020
1.1 Was the allocation sequence random?	Y	Y	Y	Y	Y
1.2 Was the allocation sequence concealed until participants were recruited and assigned to interventions?	Y	Y	Y	Y	Y
1.3 Did baseline differences between intervention groups	N	N	N	N	N[1]

suggest a problem with the randomization process?					
Risk of bias judgement	Low	Low	Low	Low	Low
2.1. Were participants aware of their assigned intervention during the trial?	N	N	N	Y	N
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	N	N	N	Y	N
2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the trial context?				Y	
2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?				Y	
2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?				N	
2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	N[2]	N[3]	N[4]	N[5]	N[6]
2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyze participants in the group to which they were randomized?	Y	Y	Y	Y	Y
Risk-of-bias judgement	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns
3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PN	Y	N	N	Y
3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	N		N	N	
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	Y		NI	Y	
3.4 If Y/PY/NI to 3.3: Is it	NI		NI	NI	

likely that missingness in the outcome depended on its true value?					
Risk-of-bias judgement	Some concerns	Low	Some concerns	Some concerns	Low
4.1 Was the method of measuring the outcome inappropriate?	Y	Y	Y	Y	N
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	N	N	N	N
4.3 If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention received by study participants?					
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?					
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?					
Risk-of-bias judgement	Low	Low	Low	Low	Low
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	Y	Y	Y	NI	N[5]
Is the numerical result being assessed likely to have been selected, on the basis of the results, from...					
5.2. ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	N	N	N	N
5.3 ... multiple eligible analyses of the data?	N	N	N	N	N
Risk-of-bias judgement	Low	Low	Low	Low	Low

Y: Yes; PY: Probably Yes; PN: Probably No; N: No; NI: No Information

[1] The proportion of patients excluded for not having a negative PCR at baseline differed by exposure arm: 13.3% in the HCQ arm and 20.4% in the control group (95% CI of the risk difference is -12.2% to -2.0%). No cases were detected among those with an inconclusive PCR at baseline (13.4% were expected if the risk was the same as for those with a negative PCR at baseline).

[2] Thirteen patients were excluded after randomization for reaching the primary endpoint before starting the study drug.

[3] Seven patients were excluded after randomization for presenting a positive test at baseline, never took the study medication or withdrew from the study.

[4] One hundred patients were excluded after randomization for presenting symptoms at the time of receiving the trial intervention. Over 10% of the remaining patients did not have complete information on the outcome because they did not complete the follow-up.

[5] Over 7% of randomized patients were excluded from the analysis for not having complete outcome data.

[6] Adjustment for age, sex, and quarantine status was not specified in the study protocol (20).